Hims & Hers Adds Cancer Screening via Galleri Partnership
Event summary
- Hims & Hers has launched the Hims & Hers Multi-Cancer Test by Galleri®, a blood test for early cancer detection.
- The test screens for signals associated with 50+ types of cancer, including those with limited screening options.
- Hims & Hers customers can add the test to existing Labs plans for a $250 discount.
- The partnership leverages GRAIL’s technology and Hims & Hers’ digital health platform to expand access to proactive cancer screening.
The big picture
Hims & Hers’ entry into cancer screening represents a strategic expansion beyond its core telehealth offerings, tapping into the growing demand for accessible and proactive healthcare solutions. This partnership with GRAIL highlights the increasing convergence of digital health platforms and advanced diagnostic technologies, potentially disrupting traditional cancer screening pathways. The move also underscores the broader trend of consumers seeking more personalized and preventative healthcare options, driven by rising healthcare costs and a desire for greater control over their health.
What we're watching
- Adoption Rate
- The success of this initiative hinges on customer adoption of the test, which will be influenced by price sensitivity and awareness of MCED benefits.
- Regulatory Scrutiny
- As MCED tests become more prevalent, increased regulatory scrutiny from the FDA and CMS is likely, potentially impacting reimbursement and test validation requirements.
- Clinical Validation
- Continued clinical validation of the Galleri test's accuracy and impact on patient outcomes will be crucial to maintain trust and expand insurance coverage.
Related topics